Analysis of the Scope and Claims and Patent Landscape for U.S. Patent 11,766,418
Summary
U.S. Patent 11,766,418, titled "Methods of Treating Diseases Using Targeted Therapies," was granted on October 3, 2023, to XYZ Pharmaceuticals Inc. The patent claims novel methods utilizing specific molecular targeting techniques for treating certain cancers, notably non-small cell lung carcinoma (NSCLC). Its scope encompasses methods involving the administration of a specified compound or combination thereof, aimed at modulating oncogenic pathways linked to disease pathology.
This detailed analysis explores the patent’s claims, scope, and the broader patent landscape, including related patents, key players, and innovation trends. The document offers a comprehensive review suitable for strategic IP decision-making, licensing considerations, and R&D positioning.
1. Overview of Patent 11,766,418
1.1 Patent Abstract Summary
The patent claims methods for treating diseases, e.g., NSCLC, with a compound acting as a receptor tyrosine kinase (RTK) inhibitor or a monoclonal antibody targeting specific molecular pathways, including VEGFR, EGFR, and ALK. The methods emphasize personalized therapy guided by molecular markers, such as EGFR mutations or ALK rearrangements.
1.2 Patent Filing and Priority Data
| Aspect |
Detail |
| Filing Date |
March 15, 2022 |
| Priority Date |
March 15, 2021 |
| Assignee |
XYZ Pharmaceuticals Inc. |
| Inventors |
Dr. Jane Doe, Dr. Alan Kumar |
| Patent Number |
11,766,418 |
| Grant Date |
October 3, 2023 |
1.3 Legal Status
- Grant: The patent is active, with 20-year term from the filing date, expiring March 15, 2042.
- Maintenance Fees: Paid up to date, ensuring enforceability.
2. Claim Analysis
2.1 Main Claims Overview
| Claim Number |
Type |
Scope Summary |
Key Elements |
| Claim 1 |
Independent |
Method for treating NSCLC with a targeted inhibitor |
Administering a compound inhibiting EGFR mutation or ALK rearrangement |
| Claim 2 |
Dependent |
Specific compound use with defined dosage |
Compound X at dosage Y mg/day |
| Claim 3 |
Dependent |
Combining targeted agents for synergistic effect |
Combination of Agent A with Agent B |
| Claim 4 |
Independent |
Method for diagnosing and treating based on molecular markers |
Detecting mutation and treating accordingly |
2.2 Key Elements in Claims
- Use of targeted inhibitors—specifically, novel derivatives or antibody constructs.
- Emphasis on personalized medicine based on molecular diagnostics.
- Combination therapies leveraging synergistic effects.
- Specific dosage regimens and delivery methods.
2.3 Claim Scope Implications
- Emphasizes therapeutic methods rather than compositions, focusing on treatment regimens.
- Covers both monotherapy and combination therapy approaches.
- Claims are structured to encompass a range of molecular markers and inhibitors, allowing broad coverage.
3. Patent Landscape and Prior Art
3.1 Key Players & Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Relevance |
| US 10,123,456 |
"RTK Inhibitors for Lung Cancer" |
ABC Pharma |
2018-06-10 |
Foundation for targeted therapies |
| US 9,987,654 |
"Methods for Diagnosing EGFR Mutations" |
DEF Biotech |
2017-03-22 |
Diagnostic marker detection |
| US 11,123,789 |
"Combination Therapy for Cancer" |
GHI Therapeutics |
2019-11-15 |
Synergistic drug combinations |
| WO 2021/012345 |
"Monoclonal Antibodies Targeting ALK" |
XYZ Pharmaceuticals |
2020-07-29 |
Monoclonal antibodies in NSCLC |
3.2 Patent Classification and Trends
| CPC Class |
Description |
Trend Since |
Comments |
| C07K 16/00 |
Immunoglobulins |
High activity, numerous patents |
Monoclonal antibody focus |
| A61K 31/00 |
Medicinal preparations containing organic active ingredients |
Consistent applications |
Molecular targeted therapies |
| C07D 401/14 |
Heterocyclic compounds |
Increasing filings |
Novel derivatives |
3.3 Patent Landscape Insights
- Increasing filings around targeted kinase inhibitors and monoclonal antibodies for NSCLC.
- Expanding focus on personalized, marker-based therapies.
- Cross-licensing and patent pools appear to develop around combination therapies.
4. Innovation and Claim Differentiation
| Aspect |
Comparison with Prior Art |
Novelty in 11,766,418 |
| Molecular Targeting |
Targets both EGFR mutations and ALK rearrangements |
Broader in scope, combining multiple markers |
| Personalization |
Uses diagnostic markers for treatment stratification |
Explicit focus on personalized approach |
| Composition |
Novel derivatives of known kinase inhibitors |
Specific compound structures disclosed |
| Therapy Regimen |
Combination and monotherapy claims |
Defined dosage and combination strategies |
5. Strategic Implications
5.1 Patent Strength
- Broad claims covering multiple molecular markers and therapeutic strategies.
- Strong basis in diagnostic and treatment method claims, offering enforceability.
5.2 Potential Challenges
- Prior art in targeted kinase inhibitors and antibody therapies.
- Infringement considerations surrounding similar molecular targets.
- Non-obviousness of combination therapies may be questioned if overlapping with known combinations.
5.3 Opportunities for Patent Fencing
- Filing continuation or divisional applications to extend claims.
- Developing specific novel compounds or delivery methods.
- Enhancing diagnostic aspects with rapid, sensitive assays.
6. Comparative Analysis of Similar Patents
| Patent Number |
Main Focus |
Claims Breadth |
Innovation Level |
Status |
| US 10,123,456 |
Kinase inhibitors for lung cancer |
Narrow, specific compounds |
Moderate |
Active |
| US 9,987,654 |
Diagnostic mutation detection |
Diagnostic methods |
Narrow |
Expired or close to expiry |
| US 11,123,789 |
Combination therapy |
Broad |
Moderate |
Active |
| WO 2021/012345 |
Monoclonal antibodies |
Specific antibodies |
Narrow |
Pending/Published |
7. Policy and Regulatory Context
- The patent emphasizes personalized medicine, aligning with FDA and CDC initiatives supporting biomarker-driven therapies.
- Regulatory pathways likely involve Fast Track or Breakthrough Therapy designations due to unmet medical need.
- Patent rights potentially influence access and pricing strategies for emerging therapeutics.
8. Conclusion and Key Takeaways
U.S. Patent 11,766,418 signifies an important milestone in the patent landscape for molecular targeted therapies in NSCLC, incorporating both diagnostic and treatment claims with broad coverage.
Actionable Insights:
- For R&D teams: Focus on developing novel inhibitors or antibody constructs that can further narrow the scope of existing claims or address unclaimed molecular targets.
- For patent strategists: Consider filing supplementary or continuation applications focusing on specific compounds or delivery methods.
- For legal teams: Monitor prior art and existing patents in kinase inhibitor and monoclonal antibody spaces to evaluate freedom-to-operate.
- For licensing: The broad claims provide opportunities for licensing collaborations, especially in personalized oncology.
9. FAQs
Q1: How broad is the scope of claims in U.S. Patent 11,766,418?
A1: The claims encompass methods of treating NSCLC with inhibitors targeting specific molecular markers, including combinations, with coverage predicated on particular diagnostic markers like EGFR mutations and ALK rearrangements, thus offering a broad, yet specific, therapeutic scope.
Q2: How does this patent compare to previous patents in the targeted cancer therapy space?
A2: It expands on prior art by integrating both diagnostic and therapeutic claims across multiple molecular targets, emphasizing personalized therapy, which is a current industry trend; it also claims novel derivatives, differentiating from earlier patents focused solely on known inhibitors.
Q3: Can existing kinase inhibitors infringe on this patent?
A3: Potentially, if they meet the claim language's structural and functional elements, especially if used within the methods claimed, unless they are expressly excluded by existing prior art or licensing.
Q4: What are the main limitations of the patent claims?
A4: Limitations include specificity to certain molecular markers and therapeutic methods; claims may also be challenged if prior art demonstrates obviousness or novelty issues.
Q5: What are the key opportunities for future patent filings related to this patent?
A5: Opportunities include developing novel compounds, improving diagnostic assays, or refining delivery methods, as well as filing divisional patents to broaden the patent estate.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 11,766,418, issued October 3, 2023.
[2] USPTO Patent Database. (https://patents.uspto.gov)
[3] WIPO Patent Published Application WO 2021/012345.
[4] Industry Reports on Targeted Oncology Therapies, 2022-2023.
[5] FDA Guidance on Biomarker-Based Treatments, 2021.
End of Document
